Scribd Logo
Upload

Welcome to Scribd!

  • 1 views

    LPL - Production Test Collection Centre Sector - 18, Block-E Rohini DELHI 110085

    Uploaded by

    shrey kedia
    Sample Reports

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    LPL - Production Test Collection Centre Sector - 18, Block-E Rohini DELHI 110085

    Uploaded by

    shrey kedia
    1 views2 pages
    Sample Reports

    Original Title

    F008

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Sample Reports

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    1 views2 pages

    LPL - Production Test Collection Centre Sector - 18, Block-E Rohini DELHI 110085

    Uploaded by

    shrey kedia
    Sample Reports

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    You are on page 1of 2

    .

    LPL - PRODUCTION TEST COLLECTION


    CENTRE
    SECTOR - 18, BLOCK-E ROHINI
    DELHI 110085

    Name : DUMMY Collected : 20/7/2022 9:53:00AM


    Received : 20/7/2022 12:46:55PM
    Lab No. : G20072023 Age: 44 Years Gender: Male Reported : 20/7/2022 12:51:28PM
    A/c Status : P Ref By : SELF Report Status :

    Test Name Results Units Bio. Ref. Interval


    CA 19.9 ;PANCREATIC CANCER MARKER, SERUM* U/mL <37.00
    (CMIA)

    Note
    1. This test is not recommended to screen Pancreatic cancer in the general population.
    2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for
    diagnosis or therapy
    3. This assay, regardless of level, should not be interpreted as absolute evidence for the presence or
    absence of malignant disease. The assay value should be used in conjunction with findings from
    clinical evaluation and other diagnostic procedures.
    4. Persistently elevated CA 19.9 levels are usually indicative of progressive malignant disease and poor
    therapeutic response
    5. The concentration of CA 19.9 in a given specimen, determined with assays from different
    manufacturers, may not be comparable due to differences in assay methods, calibration, and reagent
    specificity.

    Clinical Use
    · An aid in the management of Pancreatic cancer patients
    · Monitor the course of disease and predict recurrence in patients with Pancreatic carcinoma

    -------------------------------------------------------------
    | DISEASE | PERCENTAGE |
    | | POSITIVITY OF CA 19.9 |
    |-------------------------------------|-----------------------|
    | Pancreatic cancer | 80 |
    |-------------------------------------|-----------------------|
    | Hepatobiliary cancer | 67 |
    |-------------------------------------|-----------------------|
    | Gastric cancer | 40-50 |
    |-------------------------------------|-----------------------|
    | Hepatocellular cancer | 30-50 |
    |-------------------------------------|-----------------------|
    | Colorectal cancer | 30 |
    | ------------------------------------|-----------------------|
    | Breast cancer | 15 |
    |-------------------------------------|-----------------------|
    | Pancreatitis | 10-20 |
    |-------------------------------------|-----------------------|
    | Benign Gastrointestinal diseases | 10-20 |
    -------------------------------------------------------------

    PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

    *G20072023*
    Page 1 of 2
    .

    LPL - PRODUCTION TEST COLLECTION


    CENTRE
    SECTOR - 18, BLOCK-E ROHINI
    DELHI 110085

    Name : DUMMY Collected : 20/7/2022 9:53:00AM


    Received : 20/7/2022 12:46:55PM
    Lab No. : G20072023 Age: 44 Years Gender: Male Reported : 20/7/2022 12:51:28PM
    A/c Status : P Ref By : SELF Report Status :

    Test Name Results Units Bio. Ref. Interval

    Dr Himangshu Mazumdar Dr.Kamal Modi Dr Nimmi Kansal


    MD, Biochemistry MD, Biochemistry MD, Biochemistry
    Sr. Consultant Biochemist Consultant Biochemist Technical Director - Clinical Chemistry
    NRL - Dr Lal PathLabs Ltd NRL - Dr Lal PathLabs Ltd & Biochemical Genetics
    NRL - Dr Lal PathLabs Ltd

    Result/s to follow:
    CA 19.9 ;PANCREATIC CANCER MARKER, SERUM

    * Test conducted under NABL scope MC-2113,LPL-NATIONAL REFERENCE LAB at NEW DELHI

    IMPORTANT INSTRUCTIONS

    ŸTest results released pertain to the specimen submitted .ŸAll test results are dependent on the quality of the sample received by the Laboratory .
    ŸLaboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring
    Physician.ŸSample repeats are accepted on request of Referring Physician within 7 days post reporting.ŸReport delivery may be delayed due to
    unforeseen circumstances. Inconvenience is regretted .ŸCertain tests may require further testing at additional cost for derivation of exact value .
    Kindly submit request within 72 hours post reporting.ŸTest results may show interlaboratory variations .ŸThe Courts/Forum at Delhi shall have
    exclusive jurisdiction in all disputes /claims concerning the test(s) & or results of test(s).ŸTest results are not valid for medico legal purposes .
    ŸContact customer care Tel No. +91-11-39885050 for all queries related to test results.
    (#) Sample drawn from outside source.

    PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

    *G20072023*
    Page 2 of 2

    You might also like